Neutropenic fever and severe sepsis in adult acute myeloid leukemia (AML) patients receiving intensive chemotherapy: Causes and consequences

References

• Burnett A K. Acute myeloid leukemia: treatment of adults under 60 years. Rev Clint Exp Hematol 2002; 6: 26–45
   PubMedGoogle Scholar
• Koistinen P, Räty R, Itäliä M, Jantunen E, Koivunen E, Nousiainen T, , for the Finnish Leukemia Group, et al. Long term outcome of intensive chemotherapy for adults with de-novo acute myeloid leukemia (AML): the nationwide AML-92 study by the Finnish Leukemia Group. Eur J Haematol 2007; 78: 477–486
   PubMed Web of Science ®Google Scholar
• Elonen E, Almqvist A, Hanninen A, Jansson S E, Jarventie G, Koistinen P, et al. Comparison between four and eight cycles of intensive chemotherapy in adult acute myeloid leukemia: a randomized trial of the Finnish Leukemia Group. Leukemia 1998; 12: 1041–1048
   PubMed Web of Science ®Google Scholar
• Castaigne S, Chevret S, Archimbaud E, Fenaux P, Bordessoule D, Tilly H, et al. Randomized comparison of double induction and timed-sequential induction to a “3 + 7” induction in adults with AML: long-term analysis of the Acute Leukemia French Association (ALFA) 9000 study. Haematologica 2004; 89: 950–956
   PubMed Web of Science ®Google Scholar
• Cassileth P A, Lee S J, Litzow M R, Miller K B, Stadtmauer E A, Tallman M S, et al. for the Eastern Cooperative Oncology Group. Intensified induction chemotherapy in adult acute myeloid leukemia followed by high-dose chemotherapy and autologous peripheral blood stem cell transplantation:an Eastern Cooperative Oncology Group trial (E4995). Leuk Lymphoma 2005; 46: 55–61
   PubMed Web of Science ®Google Scholar
• Matsouka P, Pagoni M, Zikos P, Giannakoulas N, Apostolidis I, Asprogeraka T, et al. Addition of cyclosporin-A to chemotherapy in secondary (post-MDS) AML in the elderly. A multicenter randomized trial of the Leukemia Working Group of the Hellenic Society of Hematology. Ann Hematol 2006; 85: 250–256
   PubMed Web of Science ®Google Scholar
• Rintala E, Irjala K, Nikoskelainen J. Value of measurement of C-reactive protein in febrile patients with hematological malignancies. Eur J Clin Microbiol Infect Dis 1992; 11: 973–978
   PubMed Web of Science ®Google Scholar
• Santolaya M E, Cofre J, Beresi V. C-reactive protein: a valuable aid for the management of febrile children with cancer and neutropenia. Clin Infect Dis 1994; 18: 589–595
   PubMed Web of Science ®Google Scholar
• Manian F A. A prospective study of daily measurement of C-reactive protein in serum of adults with neutropenia. Clin Infect Dis 1995; 21: 114–121
   PubMed Web of Science ®Google Scholar
• Sudhoff T, Giagounidis A, Karthaus M. Serum and plasma parameters in clinical evaluation of neutropenic fever. Antibiot Chemother 2000; 50: 10–19
   PubMedGoogle Scholar
• Erten N, Genc S, Besisik S K, Saka B, Karan M A, Tascioglu C. The predictive and diagnostic values of procalcitonin and C-reactive protein for clinical outcome in febrile neutropenic patients. J Chin Med Assoc 2004; 67: 217–221
   PubMedGoogle Scholar
• Rintala E M, Aittoniemi J, Laine S, Nevalainen T J, Nikoskelainen J. Early identification of bacteremia by biochemical markers of systemic inflammation. Scand J Clin Lab Invest 2001; 61: 523–530
   PubMed Web of Science ®Google Scholar
• Kumar A, Roberts D, Wood K E, Light B, Parillo J E, Sharma S, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006; 34: 1589–1596
   PubMed Web of Science ®Google Scholar
• Arber C, Passweg J R, Fluckiger U, Pless M, Gregor M, Tichelli A, et al. C-reactive protein and fever in neutropenic patients. Scand J Infect Dis 2000; 32: 515–520
   PubMed Web of Science ®Google Scholar
• Members of the American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference Committee. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992; 20: 864–874
   PubMed Web of Science ®Google Scholar
• Levy M M, Fink M P, Marshall J C, Abraham E, Angus D, Cook D, et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International sepsis definitions conference. Crit Care Med 2003; 31: 1250–1256
   PubMed Web of Science ®Google Scholar
• Hughes W T, Armstrong D, Bodey G P, Bow E J, Brown A E, Calandra T, et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002; 34: 730–751
   PubMed Web of Science ®Google Scholar
• Ferreira F L, Bota D P, Bross A, Melot C, Vincent J L. Serial evaluation of the SOFA scores to predict outcome in critically ill patients. JAMA 2001; 10: 1754–1758
   Web of Science ®Google Scholar
• Otsuji S, Shibata H, Umeda M. Turbidimetric immunoassay of serum C-reactive protein. Clin Chem 1982; 28: 2121–2124
   PubMed Web of Science ®Google Scholar
• Madani T A. Clinical infections and bloodstream isolates associated with fever in patients undergoing chemotherapy for acute myeloid leukaemia. Infection 2000; 28: 367–373
   PubMed Web of Science ®Google Scholar
• Cherif H, Kronvall G, Björkholm M, Kalin M. Bacteraemia in hospitalised patients with malignant blood disorders: a retrospective study of causative agents and their resistance profiles during a 14-year period without antibacterial prophylaxis. Hematol J 2003; 4: 420–426
   PubMedGoogle Scholar
• Kanamaru A, Tatsumi Y. Microbiological data for patients with febrile neutropenia. Clin Infect Dis 2004; 15: S7–S10
   Web of Science ®Google Scholar
• Reuter S, Kern W V, Sigge A, Döhner H, Marre R, Kern P, et al. Impact of fluoroquinolone prophylaxis on reduced infection-related mortality among patients with neutropenia and hematologic malignancies. Clin Infect Dis 2005; 15: 1087–1093
   Web of Science ®Google Scholar
• Leibovici L, Mical P, Cullen M, Bucaneve G, Gafter-Gvili A, Fraser A, et al. Antibiotic prophylaxis in neutropenic patients. Cancer 2006; 107: 1743–1751
   PubMed Web of Science ®Google Scholar
• Lo N, Cullen M. Antibiotic prophylaxis in chemotherapy-induced neutropenia: time to reconsider. Hematol Oncol 2006; 24: 120–125
   PubMed Web of Science ®Google Scholar
• Rose P E, Johnson S A, Meakin M, Mackie P H, Stuart J. Serial study of C-reactive protein during infection in leukaemia. J Clin Pathol 1981; 34: 263–266
   PubMed Web of Science ®Google Scholar
• Yonemori K, Kanda Y, Yamamoto R, Hamaki T, Suguro M, Chizuka A, et al. Clinical value of serial measurement of serum C-reactive protein level in neutropenic patients. Leuk Lymphoma 2001; 41: 607–614
   PubMed Web of Science ®Google Scholar
• Persson L, Engervall P, Magnuson A, Vikerfors T, Söderquist B, Hansson L-O, et al. Use of inflammatory markers for early detection of bacteraemia in patients with febrile neutropenia. Scand J Infect Dis 2004; 36: 365–371
   PubMed Web of Science ®Google Scholar
• Persson L, Söderquist B, Engervall P, Vikerfors T, Hansson L-O, Tidefelt U. Assessment of systemic inflammation markers to differentiate a stable from a deteriorating clinical course in patients with febrile neutropenia. Eur J Heamatol 2005; 74: 297–303
   PubMed Web of Science ®Google Scholar